Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation
OCEANSIDE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today a newly optimized formulation of NeuroStilbene for intranasal delivery. The company has previously filed intellectual property and generated data demonstrating suppression of neuronal cell death and reduction of neuroinflammation in models of Chronic Traumatic Encephalopathy (CTE). The optimized formulation developed possesses an enhanced delivery ability and increased concentration of the active ingredient, pterostilbene.
Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the brain found in people with a history of repetitive brain trauma such as athletes and military veterans. The trauma may include symptomatic concussions as well as asymptomatic sub-concussive hits to the head that do not cause symptoms. Common symptoms of CTE in the early stages of the condition include impulse control problems, aggression, depression, and paranoia. As the disease progresses, some patients may experience problems with thinking and memory, including memory loss, confusion, impaired judgment, and eventually progresses to dementia.
“In an ideal setting, clinical implementation of NeuroStilbene requires delivery of the highest amount of pterostilbene possible in the most effective manner,” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. “The new formulation utilizes nanoparticle technology, combined with proprietary chemistry to ensure optimal concentrations of the active agent are found in the central nervous system to prevent pathology associated with neuronal injury.”
“The newly formulated NeuroStilbene is 6.6x more concentrated than our previous version which contained 30mg of nanoparticle pterostilbene per milliliter of the nanoemulsion. This new formulation contains 200mg per milliliter. This means we can deliver six times more pterostilbene intranasally per application than current formulation that is now increased from 3mg to 20mg per pump application,” said Timothy Dixon, President, and CEO of TSOI. “We are eager to start receiving feedback from our collaborators on the effects of this new formulation.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.